300347.SZ深圳证券交易所 · 创业板 ChiNext
Hangzhou Tigermed Consulting 泰格医药
Healthcare Services 医疗服务
¥58.33+¥1.52 · +2.68%
Open 开盘
¥56.90
High 最高
¥58.33
Low 最低
¥56.90
Prev Close 昨收
¥56.81
Volume 成交量
140.1万股
Turnover 成交额
¥8,092.1万
Mkt Cap 总市值
¥502亿
P/E 市盈率
549.5×
Recent Activity 近期动态All Filings 全部公告 →
23 significant filings since 31 May 2026: 1 on detention or investigation, 11 on buyback and 9 on equity incentive, and 2 other kinds. The latest, on 23 Sep 2026: 关于2026年A股限制性股票激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告.
自 31 May 2026 起有 23 份重大公告：detention or investigation 1 份、buyback 11 份、equity incentive 9 份，另有 2 类。最新一份（23 Sep 2026）：关于2026年A股限制性股票激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告。
255075100125150175
Volume 成交量
7,477.4万
20122016201920232026
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Relative Value 同业比较
Healthcare Services 医疗服务 · 54 listed peers
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥502亿 | ¥73亿 | 6th highest of 54 · 54 家中第 6 高 | |
| Trailing P/E 市盈率 | 549.5x | 103.9x | 3rd highest of 38 · 38 家中第 3 高 | |
| P/B 市净率 | 2.6x | 3.4x | 15th lowest of 54 · 54 家中第 15 低 | |
| Revenue Growth 营收增速 | 14.1% | 4.0% | 17th highest of 54 · 54 家中第 17 高 | |
| Profit Growth 净利增速 | -207.8% | 3.3% | 4th lowest of 54 · 54 家中第 4 低 | |
| Gross Margin 毛利率 | 27.5% | 33.3% | 16th lowest of 54 · 54 家中第 16 低 | |
| Net Margin 净利率 | -5.0% | 5.8% | 11th lowest of 54 · 54 家中第 11 低 | |
| Return on Equity 净资产收益率 | -2.0% | 2.0% | 13th lowest of 54 · 54 家中第 13 低 | |
| Debt to Assets 资产负债率 | 17.2% | 28.7% | 14th lowest of 54 · 54 家中第 14 低 | |
| Grade Score 评级得分 | 40 | 52 | 17th lowest of 53 · 53 家中第 17 低 |
Statement figures are for the period to 30 Jun 2026, filed by 54 of 54 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，54 家同业中 54 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
Largest Peers 主要同业
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Wuxi Apptec 药明康德 | ¥4,956亿 | 22.9x | 5.8x | 38.9% | 38.5% | 13.2% | B |
| Pharmaron Beijing 康龙化成 | ¥807亿 | 47.1x | 4.9x | 17.9% | 9.4% | 4.6% | C |
| Aier Eye Hospital Group 爱尔眼科 | ¥737亿 | 29.0x | 3.2x | 3.8% | 12.9% | 6.0% | C |
| Asymchem Laboratories 凯莱英 | ¥650亿 | 62.8x | 3.7x | 13.1% | 14.3% | 2.9% | C |
| Biocytogen 百奥赛图 | ¥568亿 | 155.0x | 23.4x | 51.6% | 25.6% | 10.5% | B |
| Hangzhou Tigermed Consulting 泰格医药 | ¥502亿 | 549.5x | 2.6x | 14.1% | -5.0% | -2.0% | D |
| Joinn 昭衍新药 | ¥346亿 | 35.2x | 3.9x | 5.3% | 106.2% | 8.6% | B |
| Haoyuan Chemexpress 皓元医药 | ¥215亿 | 83.0x | 6.7x | 25.7% | 9.8% | 5.3% | C |
| BGI Genomics 华大基因 | ¥186亿 | — | 2.2x | 9.6% | 2.7% | 0.6% | D |
| Meinian Onehealth Healthcare Holdings 美年健康 | ¥175亿 | 54.0x | 2.2x | -6.4% | -5.0% | -2.2% | E |
| Hitgen 成都先导 | ¥173亿 | 123.1x | 11.3x | 52.4% | 23.0% | 5.2% | B |
| Topchoice Medical 通策医疗 | ¥149亿 | 24.2x | 3.6x | 4.1% | 32.8% | 9.5% | C |
| Gempharmatech 药康生物 | ¥147亿 | 80.5x | 6.5x | 22.6% | 24.1% | 4.8% | B |
| Jiuzhou Pharma 九洲药业 | ¥144亿 | 24.3x | 1.6x | -10.3% | 14.8% | 4.3% | C |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。